Cisplatin + gemcitabine (urothelial neoadj + metastatic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CISPLATIN` `DRUG-GEMCITABINE`

ID	`REG-CISPLATIN-GEMCITABINE-UROTHELIAL`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-EAU-BLADDER-2024` `SRC-NCCN-BLADDER-2025`

Notes

Workhorse cisplatin-doublet. Galsky cisplatin-eligibility critical.

Used By

Indication

IND-UROTHELIAL-2L-PLATINUM-CHEMO - IND-UROTHELIAL-2L-PLATINUM-CHEMO
IND-UROTHELIAL-METASTATIC-1L-PLATINUM-CHEMO-AVELUMAB - IND-UROTHELIAL-METASTATIC-1L-PLATINUM-CHEMO-AVELUMAB

Regimen

REG-GEM-CARBO-UROTHELIAL - Gemcitabine + carboplatin (urothelial carcinoma, cisplatin-ineligible)